WASHINGTON— The Trump administration on Monday unveiled a sweeping plan that goals to decrease prescription drug costs — however its influence on the pharmaceutical trade stays to be seen.
The plan depends on drugmakers hanging offers with the U.S. authorities to decrease their costs, with a risk of latest authorities regulation and authorized investigations in the event that they don’t. It requires basing U.S. drug costs on these paid by different nations, aiming to slash costs within the U.S. and push them up abroad by way of commerce coverage.
Nonetheless, traders responded positively to the information, because the NYSE ARCA Biotechnology Index rose virtually 3% and the ARCA Pharmaceutical Index rose 1.5% in morning buying and selling. One motive could also be that lots of the methods the plan seeks to impose penalties on pharmaceutical corporations, resembling importing medicines from different nations, have proved cumbersome to execute previously or have run into authorized challenges.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
